UK and Austrian mass spec agreement
Oxford Medical Diagnostics, a UK developer of breath based, medical diagnostic technology for the diagnosis and monitoring of metabolic and infectious diseases; and V&F Analyse- und Messtechnik, an Austrian provider of analytical instruments, announced a strategic alliance focusing on the area of mass spectrometry.
Oxford Medical Diagnostics, a UK developer of breath based, medical diagnostic technology for the diagnosis and monitoring of metabolic and infectious diseases; and V&F Analyse- und Messtechnik, an Austrian provider of analytical instruments, announced a strategic alliance focusing on the area of mass spectrometry.
Under the terms of the new agreement, Oxford Medical Diagnostics will offer and support V&F’s high-performance mass spectrometry analysers in the UK and Ireland and establish a contract batch sample analysis service in its Oxford laboratories.
“This is a great alliance for OMD, linking us to one of the most talented molecular analysis companies in the world. It brings analytical know-how, and the opportunity to earn revenues,” said Oxford Medical Diagnostics CEO, Tony Marchington.
Target markets for the technology and analytical services include pharmaceutical, biotechnology, aerospace, fine chemicals, oil and gas, environmental and food and beverage analysis. OMD currently uses V&F’s technology to compare clinical results from diabetic patients with OMD’s proprietary laser-based breath analysis solutions.
In addition to this collaboration, the two companies report that they are looking into other opportunities for joint research. These include bacterial headspace analysis, as well as sports performance monitoring and healthy weight loss management.
For more information visit omdiagnostics.com and www.vandf.com
The Complexity of Oligonucleotide Separations
January 9th 2025Peter Pellegrinelli, Applications Specialist at Advanced Materials Technology (AMT) explains the complexity of oligonucleotide separations due to the unique chemical properties of these molecules. Issues such as varying length, sequence complexity, and hydrophilic-hydrophobic characteristics make efficient separations difficult. Separation scientists are addressing these challenges by modifying mobile phase compositions, using varying ion-pairing reagents, and exploring alternative separation modes like HILIC and ion-exchange chromatography. Due to these complexities, AMT has introduced the HALO® OLIGO column, which offers high-resolution, fast separations through its innovative Fused-Core® technology and high pH stability. Alongside explaining the new column, Peter looks to the future of these separations and what is next to come.
Metabolomics Analysis of Low Birth-Weight Infants Using UHPLC-MS/MS Following Lipid Emulsion
January 10th 2025A recent study aimed to directly compare the changes in serum metabolites among very low birth-rate (VLBW) infants following the administration of the soybean oil-based lipid emulsion and soybean oil, medium-chain triglycerides, olive oil, and fish oil (SMOF) lipid emulsion using untargeted metabolomics techniques.
Analyzing New Drug Modalities: An ISC 2024 Interview with Kelly Zhang
January 10th 2025At ISC 2024 in Liverpool, United Kingdom, LCGC International interviewed Kelly Zhang of Genentech about her work analyzing new drug modalities, such as mRNA, oligonucleotides, peptides, and cell and gene therapies.
